NKIRAS2 Antibody

Code CSB-PA873696LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human tonsil tissue using CSB-PA873696LA01HU at dilution of 1:100

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) NKIRAS2 Polyclonal antibody
Uniprot No.
Target Names
NKIRAS2
Alternative Names
DKFZP434N1526 antibody; I kappa B interacting Ras like protein 2 antibody; I-kappa-B-interacting Ras-like protein 2 antibody; Kappa B Ras protein 2 antibody; Kappa B-Ras protein 2 antibody; KappaB Ras2 antibody; KappaB-Ras2 antibody; KBRAS 2 antibody; KBRAS2 antibody; KBRS2_HUMAN antibody; MGC74742 antibody; NF kappa B inhibitor interacting Ras like protein 2 antibody; NF-kappa-B inhibitor-interacting Ras-like protein 2 antibody; NFKB inhibitor interacting Ras like 2 antibody; NFKB inhibitor interacting Ras like protein 2 antibody; NKIRAS 2 antibody; NKIRAS2 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human NF-kappa-B inhibitor-interacting Ras-like protein 2 protein (1-191AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The NKIRAS2 Antibody (Product code: CSB-PA873696LA01HU) is Non-conjugated. For NKIRAS2 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA873696LB01HU NKIRAS2 Antibody, HRP conjugated ELISA
FITC CSB-PA873696LC01HU NKIRAS2 Antibody, FITC conjugated
Biotin CSB-PA873696LD01HU NKIRAS2 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Atypical Ras-like protein that acts as a potent regulator of NF-kappa-B activity by preventing the degradation of NF-kappa-B inhibitor beta (NFKBIB) by most signals, explaining why NFKBIB is more resistant to degradation. May act by blocking phosphorylation of NFKBIB and nuclear localization of p65/RELA NF-kappa-B subunit. It is unclear whether it acts as a GTPase. Both GTP- and GDP-bound forms block phosphorylation of NFKBIB.
Gene References into Functions
  1. GBM cells overexpressing TNFAIP3 and NKIRAS2 were refractory to miR-125b-induced apoptosis resistance as well as TMZ resistance, indicating that both genes are relevant targets of miR-125b. PMID: 24901050
  2. KappaB-Ras2 is a nuclear-cytoplasmic small GTPase that inhibits NF-kappaB activation through the suppression of transcriptional activation of p65/RelA. PMID: 20639196
Subcellular Location
Cytoplasm.
Protein Families
Small GTPase superfamily, Ras family, KappaB-Ras subfamily
Tissue Specificity
Widely expressed.
Database Links

HGNC: 17898

OMIM: 604497

KEGG: hsa:28511

STRING: 9606.ENSP00000303580

UniGene: Hs.632252

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*